Verapamil and simvastatin — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Increased simvastatin exposure and myopathy risk
Verapamil inhibits metabolism of simvastatin and can increase myopathy risk. Dose limits or alternative statin therapy should be considered. In this scenario, the correct option is increased simvastatin exposure and myopathy risk. The other options are plausible but do not address the key clinical, legal or safety issue as directly. This aligns with UK pharmacy practice guidance cited in the reference field.
Reference: https://www.pharmacyregulation.org/registration-assessment#stage-8-order-62